Gilead Sciences, Inc. (NASDAQ:GILD) Expected to Post Earnings of $1.54 Per Share

Wall Street brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) to announce earnings per share of $1.55 for the current quarter, according to Zacks. Seven analysts have made estimates for Gilead Sciences’ earnings. The highest EPS estimate is $1.73 and the lowest is $1.29. Gilead Sciences reported earnings per share of $1.87 during the same quarter last year, which would suggest a negative year over year growth rate of 17.1%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Gilead Sciences will report full-year earnings of $6.55 per share for the current financial year, with EPS estimates ranging from $6.42 to $6.94. For the next year, analysts expect that the business will report earnings of $6.34 per share, with EPS estimates ranging from $4.97 to $7.30. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Gilead Sciences.

Gilead Sciences (NASDAQ:GILD – Get Rating) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.32. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.08 earnings per share.

A number of equities analysts have weighed in on the company. Bank of America lowered their price target on Gilead Sciences from $73.00 to $71.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 2nd. Oppenheimer lowered their price target on Gilead Sciences from $100.00 to $90.00 in a research report on Thursday, February 3rd. BMO Capital Markets began coverage on Gilead Sciences in a report on Tuesday, March 8th. They set a “hold” rating and a $65.00 price objective for the company. Morgan Stanley reduced their price objective on Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating for the company in a report on Tuesday, April 12th. Finally, Barclays reduced their price objective on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a report on Thursday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus price target of $73.38.

Shares of NASDAQ GILD opened at $60.31 on Tuesday. The business’s 50 day moving average price is $60.51 and its two-hundred day moving average price is $65.60. The company has a market cap of $75.62 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 0.42 and a beta of 0.38. The company has a quick ratio of 1.23, a current ratio of 1.54 and a debt-to-equity ratio of 1.74. Gilead Sciences has a twelve month low of $57.19 and a twelve month high of $74.12.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 29th. Investors of record on Wednesday, June 15th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 4.84%. The ex-dividend date of this dividend is Tuesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 81.56%.

In related news, EVP Brett A. Pletcher sold 1,691 shares of the business’s stock in a transaction that occurred on Wednesday, February 9th. The stock was sold at an average price of $63.89, for a total value of $108,037.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 3,634 shares of the company’s stock in a transaction on Friday, March 11th. The stock was sold at an average price of $58.24, for a total value of $211,644.16. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Landmark Wealth Management LLC bought a new stake in Gilead Sciences during the first quarter worth $30,000. FSB Premier Wealth Management Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth $28,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of Gilead Sciences during the first quarter worth $25,000. OLD Second National Bank of Aurora increased its holdings in shares of Gilead Sciences by 46.3% during the third quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 139 shares in the last quarter. Finally, Capital Advisors Ltd. LLC increased its holdings in shares of Gilead Sciences by 127.6% during the fourth quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 250 shares in the last quarter. Hedge funds and other institutional investors own 80.16% of the company’s stock.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More